Consent in Alzheimer's disease research: risk/benefit factors.
In the era of chronic disease, we are challenged to find therapies that provide symptomatic relief and ideally, alter the course of the underlying disease. In Alzheimer's disease (AD), these issues are complicated by the disease itself, which affects the subject's decision-making capacity for participation in the research. According to established ethical guidelines it is clear that individuals with impaired capacity may participate in research and their risk should be no greater than that which the individual would have in day to day activities with anticipation of benefits within that realm. Decision making processes are complex and involve proxies who themselves have biases about their loved one and the potential for participating in the research. Newer disease-modifying approaches such as immunotherapy have potential for affecting the course of the underlying disease but with greater risk of more significant side effects. Ideally the health care of the subjects is not disadvantaged by research participation. At the same time, trials of potentially riskier therapy are relevant in subjects with the disease. Research for subjects with AD must have appropriate safeguards in place to enable effective progress in innovative therapy for a vulnerable, often elderly population. Recommendations are made which could further our capacity to undertake ethical research in the AD population.
Beattie
B Lynn
BL
Department of Medicine, Division of Geriatric Medicine, University of British Columbia, Vancouver, BC, Canada.
D000544:Alzheimer Disease / Q000503:physiopathology / Q000523:psychology / Q000628:therapy*; D002170:Canada; D002985:Clinical Protocols / Q000592:standards*; D002986:Clinical Trials as Topic / Q000941:ethics / Q000592:standards*; D006801:Humans; D007167:Immunotherapy / Q000009:adverse effects; D007258:Informed Consent / Q000331:legislation & jurisprudence / Q000523:psychology / Q000592:standards*; D016743:Mental Competency / Q000523:psychology / Q000592:standards*; D018697:Nootropic Agents / Q000009:adverse effects; D018579:Patient Selection / Q000941:ethics; D018570:Risk Assessment / Q000941:ethics / Q000592:standards; D028761:Withholding Treatment / Q000941:ethics / Q000592:standards
D018697:Nootropic Agents